Sunho Biologics Inc

Sunho Biologics Inc a biopharmaceutical company engages in the discovery development and commercialization of biologics that regulate immune microenvironment by modulating the innate and adaptive immune systems It offers IAH0968 an antibodydependent cell mediated cytotoxicity enhanced monoclonal antibody which is in the Phase II clinical trials for biliary tract carcinoma and colorectal cancer CRC The company also provides IAP0971 and IAE0972 immunocytokines which have completed Phase I clinical trials for advanced solid tumors including nonsmall cell lung cancer and CRC In addition its preclinical stage products include IBB0979 an immunocytokine for solid tumors IBC0966 a clinical stage antiPDL1 antibodysignal regulatory protein bifunctional fusion protein for tumor specific immune responses IBD0333 for tumor cells IAN0982 for oncology and ISH0988 and ISH0613 immunosuppressors focused on autoimmune diseases The company was founded in 2018 and is headquartered in Huzhou China Sunho Biologics Inc is a subsidiary of Sunho Wisdom Investments Limited